Clinical trials: Covid19 Vaccine
COVID-19, Vaccine Immune Response
COVID-19 Vaccine Reactogenicity and Immunogenicity
Analysis of antibody kinetics after vaccination with mRNA-1273 and factors influencing the vaccine immunogenicity
- Conditions
- COVID-19, Vaccine Immune Response, Vaccine Adverse Reaction
- Trial name
- NCT05258708
- Testing
- mRNA-1273 COVID-19 vaccine
- Where
- 5 sites in South Korea
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Covid19 Vaccine
Covid-19 Vaccine Response in Elderly Subjects
The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over time, defined here at 9…
- Trial name
- MONITOCOVAGING (NCT04760704)
- Testing
- Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration
- Where
- France
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Severe Acute Respiratory Infection (SARI), Influenza
Measure of Vaccine Effectiveness to Prevent Hospitalizations for Viral Respiratory Infections in Adults
This study is a prospective, multicentric, observational test negative design study on adults hospitalized for Severe Acute Respiratory Infection (SARI), regardless of their vaccination status.
- Conditions
- Severe Acute Respiratory Infection (SARI), Influenza, COVID-19
- Trial name
- RESPIVAC (NCT05582239)
- Where
- 8 sites in France
- Volunteers
- 2,400 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
COVID-19, SARS-CoV-2
Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
- Trial name
- NCT05876364
- Testing
- QTP104 1ug, QTP104 5ug, QTP104 25ug
- Where
- 2 sites in South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
COVID-19
Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean
This multi-country study seeks to collect real-world evidence (RWE), from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes…
- Trial name
- NCT05475704
- Where
- 5 sites in Argentina, Colombia and 2 more
- Volunteers
- 59 people
- Sponsor
- P95
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05033847
- Testing
- Recombinant COVID-19 Vaccine (CHO cell), COVID-19 vaccine (Vero cells)
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine
Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O, Ad5-nCoV/O-IH or mRNA-based…
- Trial name
- NCT05442684
- Testing
- Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation, mRNA-based COVID-19 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized
Randomized controlled trial to evaluate safety, immunogenicity and efficacy of three different doses (10, 25 and 50 mcg) of a novel vaccine compared with placebo in adult volunteers previously immunized against Covid-19 with…
- Trial name
- NCT05016934
- Testing
- A vaccine composed of a recombinant S1 antigen
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital do Coracao
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III
A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years…
- Trial name
- COVID-19 (NCT05096845)
- Testing
- Recombinant SARS-CoV-2 fusion protein vaccine (V-01), Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- Where
- 25 sites in Indonesia, Philippines and 1 more
- Volunteers
- 22,500 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19, Vaccine Adverse Events of Special Interest
EU Secondary Data Post-Authorisation Safety Study of AZD1222
A study based on electronic heath records will evaluate the incidence and relative risk of safety concerns and adverse events of special interest (AESIs) following immunisation by AZD1222 in the real-world setting.
- Trial name
- D8111R00006 (NCT05126992)
- Testing
- AZD1222
- Where
- 4 sites in Netherlands, Spain and 1 more
- Volunteers
- 5,321,930 people
- Sponsor
- AstraZeneca
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19, Vaccines
Text-based Reminders to Promote COVID-19 Vaccinations
This study investigates whether and which type of text-based reminders affect the take-up of the COVID-19 vaccine.
- Trial name
- NCT04801524
- Testing
- Self-benefit, Prosocial-benefit, Early access
- Where
- United States
- Volunteers
- 250,000 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
COVID-19, SARS-CoV-2
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05477186
- Testing
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg)
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19, Blood Pressure
Short-term Effect of COVID-19 Vaccine on Blood Pressure
To investigate short-term effect of COVID-19 vaccination on blood pressure by conducting 24-hour ABPM
- Trial name
- NCT05013931
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
COVID-19
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
The purpose of this study is to assess the immunogenicity and safety of SCB-2023B monovalent Omicron XBB.1.5 vaccine compared to the prototype SCB-2019 vaccine in participants previously vaccinated with 3 doses of inactivated…
- Trial name
- NCT06567457
- Testing
- SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19, SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Vaccine Preventable Disease
Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations
A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants.
- Trial name
- CERC (NCT04765839)
- Testing
- Educational, culturally appropriate COVID-19 messages
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.